<DOC>
	<DOCNO>NCT02961816</DOCNO>
	<brief_summary>The goal clinical research study learn safety effectiveness combination panobinostat , gemcitabine , busulfan , melphalan , either without rituximab , patient non-Hodgkin 's Hodgkin 's lymphoma receive stem cell transplant .</brief_summary>
	<brief_title>Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant Patients With Refractory/Relapsed Lymphoma</brief_title>
	<detailed_description>Busulfan Test Dose : Participant receive test dose busulfan vein 60 minute . Before participant receives low-level test dose busulfan , blood drawn several time check level busulfan participant 's blood change time . This call pharmacokinetic ( PK ) test . This information use decide next dose need reach correct blood level match participant 's body size . Participant likely receive test dose outpatient week participant admit hospital . If give outpatient , participant admit hospital Day -11 ( 11 day participant 's stem cell return participant 's body ) test dose give Day -10 . Blood ( 1 teaspoon time ) drawn PK test 11 time participant 's test dose busulfan 10 time 11 hour dose . The blood sample repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place participant 's vein lower number needle stick need draws . If possible PK test perform reason , participant receive standard fix dose busulfan . Study Drug Administration : On Days -13 -11 ( 3 day participant admit hospital ) , participant receive palifermin vein 30 second day help decrease risk side effect mouth throat . On Day -9 Day -2 , participant take panobinostat mouth , food . The study staff tell participant many tablet take . Participant receive dexamethasone vein 3-5 minute 2 time day . On Day -9 , participant type B-cell cancer , participant receive rituximab ( treatment use certain lymphoma ) vein 3-6 hour part participant 's standard care . The study doctor tell participant participant receive rituximab . On Day -8 , participant receive gemcitabine vein 4½ hour . On Days -8 , -7 , -6 , -5 , participant receive busulfan vein 60 minute . On Day -3 , participant receive gemcitabine vein 4½ hour melphalan vein 30 minute . On Day -2 , participant receive melphalan vein 30 minute . On Day -1 , participant rest ( participant receive chemotherapy ) . On Day 0 , participant receive participant 's stem cell vein 30-60 minute . Participant receive 3 dos palifermin vein , 15-30 second time , Days 0 , +1 , +2 . As part standard care , participant receive G-CSF ( filgrastim ) injection participant 's skin 1 time day start Day +5 participant 's blood cell level return normal . The study doctor discus participant , include filgrastim give risk . Length Study : As part standard care , participant remain hospital 3-4 week transplant . After participant release hospital , participant continue outpatient . Participant need stay Houston area check infection side effect . Participant take study 100 day transplant . Participant may take study early disease get bad , intolerable side effect occur , participant unable follow study direction . Study Tests : About 100 day transplant : - Participant physical exam . - Blood ( 4 teaspoon ) urine collect routine test . - If doctor think need , participant may bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration/biopsy , area hip numb anesthetic , small amount bone marrow bone withdrawn large needle . This investigational study . Panobinostat melphalan FDA approve commercially available treatment multiple myeloma ( MM ) . Busulfan FDA approve commercially available treatment leukemia . Gemcitabine FDA approve commercially available treatment lymphoma , breast cancer , lung cancer . Rituximab FDA approve commercially available treatment non-Hodgkin 's lymphoma . The use study drug combination investigational . The study doctor explain study drug design work . Up 75 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>1 . Age 1565 2 . Patients : DLBCL one following : 1 . Primary refractory ( CR 1st line ) ; 2 . Highrisk relapse ( CR1 &lt; 6 month , secondary IPI &gt; 1 high LDH ) ; , 3 . Refractory relapse : No response ( SD PD ) &gt; /= 1 line salvage . 3 . Hodgkin 's one following : 1 . Primary refractory ( CR 1st line PD within 3 month ) ; 2 . Highrisk relapse ( CR1 &lt; 1 year , extranodal relapse B symptom ) ; , 3 . Refractory relapse : No response ( SD PD ) &gt; /= 1 line salvage . 4 . TNHL one following : 1 . Primary refractory ( &lt; /= CR 1st line relapse within 6 month ) ; , 2 . Nonresponsive ( SD/PD ) &gt; /= 1 line salvage . 5 . Adequate renal function , define estimate serum creatinine clearance &gt; /= 50 ml/min and/or serum creatinine &lt; /= 1.8 mg/dL 6 . Adequate hepatic function ( SGOT and/or serum glutamate pyruvate transaminase ( SGPT ) &lt; /= 3 x upper limit normal ( ULN ) ; bilirubin ALP &lt; /= 2 x ULN 7 . Adequate pulmonary function force expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) ( correct Hgb ) &gt; /= 50 % 8 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease 9 . PS &lt; 2 10 . Negative Beta human chorionic gonadotropin ( HCG ) woman childbearing potential 1 . Grade &gt; /= 3 nonhematologic toxicity prior therapy resolve &lt; /= G1 2 . Prior whole brain irradiation 3 . Corrected QT interval ( QTc ) long 500 m 4 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /= 10,000 copies/mL , &gt; /= 2,000 IU/mL ) 5 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology 6 . Active infection require parenteral antibiotic 7 . HIV infection , unless receive effective antiretroviral therapy undetectable viral load normal cluster differentiation 4 ( CD4 ) count 8 . Radiation therapy month prior enroll</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Refractory/Relapsed Lymphoma</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>T-cell Lymphoma</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589B</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Caphosol</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Enterex</keyword>
	<keyword>Glutapak-10</keyword>
	<keyword>NutreStore</keyword>
	<keyword>Resource</keyword>
	<keyword>GlutaSolve</keyword>
	<keyword>Sympt-X G.I .</keyword>
	<keyword>Sympt-X</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Stem cell transplant</keyword>
</DOC>